Lifeboat Foundation

That’s why Ellington sees a more immediate use for the technology in the up-and-coming field of DNA data storage. Large tech firms and startups alike are evaluating whether nucleotides can beat out silicon when it comes to long-term, archival information storage. DNA is notoriously data-dense, and the arrival of hachimoji just doubled its information-carrying capacity.

But first, chemists hope to improve DNA data storage and churn out new medical compounds.

Focus of the drive is to increase number of South Asian donors.

The senior girls team will be heading to the provincials for the first time in the school’s history.

Continue reading “Family hosts stem cell donor drive at Surrey gurdwara for relative’s second time battling cancer” »

Artificial intelligence experts, ethicists and diplomats debated autonomous weapons. Christopher Intagliata reports.

Full Transcript

Think killer robots. What comes to mind? Maybe…this guy?

Continue reading “Should Robots Have License to Kill” »

WFIRST ain’t your grandma’s space telescope. Despite having the same size mirror as the surprisingly reliable Hubble Space Telescope, clocking in at 2.4 meters across, this puppy will pack a punch with a gigantic 300 megapixel camera, enabling it to snap a single image with an area a hundred times greater than the Hubble.

With that fantastic camera and the addition of one of the most sensitive coronagraphs ever made – letting it block out distant starlight on a star-by-star basis – this next-generation telescope will uncover some of the deepest mysteries of the cosmos.

Continue reading “Meet WFIRST, The Space Telescope with the Power of 100 Hubbles” »

Amazon CEO Jeff Bezos wants to send its first passengers to space as soon as this year. Bezos spoke during a private event at the Yale Club in New York City, Business Insider reports.

“This year. This is the first time I’ve ever been saying, ”this year.” For a few years, I’ve been saying, ”next year,” Bezos told Jeff Foust, senior staff writer at Space News, during the event.

The billionaire’s private space tourism company Blue Origins has been making some big strides towards that goal in recent years. Its flagship suborbital vehicle New Shepard reached the so-called Kármán line (62 miles or 100 km), widely agreed to be the edge of outer space, for the first time during a test flight in 2015.

NASA has given the green light for Elon Musk’s SpaceX to launch the first unmanned test of its seven-seat Crew Dragon capsule on March 2 after passing a full day of reviews, bringing the space agency one step closer to replacing the retired Space Shuttle program after years of delays and ending its dependency on contracted Russian Soyuz rockets.

The test flight was originally scheduled for January, but was later delayed to complete hardware testing and other reviews. Per Space.com, NASA and SpaceX officials have now completed an in-depth review of the Crew Dragon’s capabilities called a flight readiness review, with NASA Commercial Crew Program manager Kathy Leuders telling reporters they needed to verify the craft “can safely go rendezvous and dock with the space station, and undock safely, and not pose a hazard to the International Space Station.”

Now, the team is trying to better understand what he and the team found and its practical implications.

“One way or another, this technology is coming. These cars are already being tested in cities,” Richard Ezike, the lead author of the study, said in an organization-published press release. “If we do not plan and set out thoughtful policies, driverless cars could exacerbate the challenges we see in transportation today — especially for underserved communities.”

Take the Bus

The researchers argue that cities that introduce autonomous vehicles should also invest in public transit, to make sure that those who have longer commutes and would get stuck in the newly-introduced congestion can still find and make it to their jobs.

Roche could pay $5 billion for biotech company Spark Therapeutics. The pharma giant likely wants to expand its presence in hemophilia, a lucrative market.